Could an immune drug ease schizophrenia symptoms?
NCT ID NCT07680946
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial tests whether ublituximab, an immune-modulating drug, can reduce symptoms in people with treatment-resistant schizophrenia. Participants receive the drug by IV infusion, and researchers measure changes in symptom scores over time. The goal is to see if targeting the immune system might help when standard antipsychotics fail.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ublituximab (also known as BRIUMVI)
What this could lead to
If successful, this could point toward a new treatment option for people with schizophrenia who do not respond to standard antipsychotics.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause infusion reactions or infections, and its effect on schizophrenia symptoms is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain Stimulation for Schizophrenia Negative Sym NCT07680959
- Sleep Brain Stimulation Study for Schizophrenia NCT07680114
- TV-44749 Schizophrenia Trial (NCT06253546)
- Cognitive Training for Older Adults with Schizop NCT07658391
- Sodium Benzoate for Treatment-Resistant Schizoph NCT06340789
- GABA Function in Psychosis Study (NCT04004416)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••